About Decisiondx News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Late-Breaking Data Presented at the 2023 AAD Annual Meeting Demonstrates Improved Accuracy of DecisionDx®-SCC in Predicting Metastatic Risk Over Traditional Staging Systems in Independent, Multi-Center Cohort Study

Study data shows consistent independent risk stratification performance of DecisionDx-SCC in a novel cohort of patients with cutaneous squamous cell carcinoma and one or more risk factors . | March 18, 2023

United statesCastle biosciencesAmerican joint committee on cancerCastle biosciences incOrleans ernestn morial convention center theaterSecurities exchangeBreaking researchNew orleans ernestAbout decisiondxMypath melanomaSecurities actSecurities exchange actAnnual reportAmerican joint committeeNc stock exchangePress release

New Data from DECIDE Study Show the Significant Role of DecisionDx®-Melanoma Test Results and Patient Preference in Decisions to Perform the Sentinel Lymph Node Biopsy (SLNB) Surgical Procedure

Study data also show that using certain DecisionDx-Melanoma test results in conjunction with current guidelines can reduce the number of SLNB procedures performed, particularly in patients with a low. | October 20, 2022

United kingdomUnited statesCity ofCastle biosciencesJ michael guentherCastle biosciences incInternational congressSecurities exchangeSociety for melanoma researchElizabeth physiciansMelanoma researchAbout decisiondxMypath melanomaSecurities actSecurities exchange actQuarterly report

Castle Biosciences (CSTL) Reports New Data from DECIDE Showing Significant Role of DecisionDx-Melanoma Test Results

Castle Biosciences (CSTL) Reports New Data from DECIDE Showing Significant Role of DecisionDx-Melanoma Test Results
streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.

United kingdomUnited statesCity ofCastle biosciencesCamilla zuckeroJ michael guentherCastle biosciences incInternational congressSecurities exchangeSociety for melanoma researchElizabeth physiciansMelanoma researchAbout decisiondxMypath melanomaSecurities actSecurities exchange act

Expanded SEER Registries Dataset Shows Improved Survival for DecisionDx-Melanoma Tested Patients Compared to Untested Patients

In a recent study, patients diagnosed with melanoma and tested with DecisionDx-Melanoma had improved survival (27% improvement in melanoma-specific survival) compared to untested patients.

Derek maetzoldCastle biosciencesCamilla zuckeroDecisiondx diffdxTexas castle biosciences incNational cancer instituteEuropean association of dermato oncologyCastle biosciences incSecurities exchangeEnd resultsEuropean associationDermato oncologyDecisiondx melanoma classAbout decisiondxIntegrated testPath melanoma